Experience with hormone receptors in renal cancer.
The hormone receptor concentrations in tumour tissues from 20 renal carcinoma patients were determined before postoperative medroxyprogesterone acetate (MPA) therapy was started. Except for glucocorticoid receptors, the concentrations were either not measurable or were extremely low. The question is whether MPA therapy, solely on the strength of its character as a general roborant, is still useful in the treatment of renal tumours, even when it fails to exercise primary influence because of the absence of suitable receptors. None of the 20 patients was treated with MPA.
Romics
I
I
Department of Urology, St. Agnes Hospital, Bocholt, FRG.
Rüssel
C
C
Bach
D
D
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000737:chemistry*; D006801:Humans; D007668:Kidney / Q000737:chemistry*; D007680:Kidney Neoplasms / Q000737:chemistry*; D008525:Medroxyprogesterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D011956:Receptors, Cell Surface / Q000032:analysis*
D000970:Antineoplastic Agents; D011956:Receptors, Cell Surface; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone